PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
REGULATORY
METI Seeks 7.2 Bil. Yen for Drug Discovery, 3.5 Bil. for Regenerative Medicine
The Ministry of Economy, Trade and Industry (METI) is seeking 673.3 billion yen in science-related budgets for FY2017, beginning next April, compared to the 545.8 billion yen initial budget allocated in FY2016. METI’s total budget request, released on August 31,…
To read the full story
Related Article
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
August 24, 2016
- MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
August 24, 2016
- MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
August 23, 2016
- MHLW to Seek Budgets to Develop Artificial Intelligence for Drug Discovery
August 22, 2016
REGULATORY
- AbbVie’s Fast-Acting Botulinum Toxin Boey Wins Japan Panel Backing
October 27, 2026
- LDP Lawmakers Renew Push for Routine HPV Shots for Males by April 2027
October 27, 2026
- LDP Study Group Eyes Policy Proposals to Shore Up Drug Supplies
October 27, 2026
- FPMAJ Seeks Higher Drug Prices to Bolster Supply Security: LDP Confab
October 27, 2026
- PMDA Says IT Systems Could Go Offline Without Warning
October 27, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…